| April 2 |
Data on Telavancin and Micafungin Hold Promise of New Therapeutic
Options in Fight Against Serious Infectious Disease |
| April 2 |
Helix BioPharma Corp. Announces Positive Phase II Clinical Results
with its Topical Interferon Alpha-2b |
| April 2 |
Six Important Things to Know About Preventing Hospital Infections |
| April 2 |
Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million
Annually |
| April 2 |
NeoPharm Provides Update on LE-SN38 Program |
| April 2 |
Immunosuppressant Drug Prevents Tobacco Induced Lung Cancer in Mice |
| April 2 |
Large Study Shows that Presence of Neutralizing Antibodies Did Not
Predict Clinical Response to Betaseron Treatment |
| April 2 |
M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data
at the AACR Annual Meeting |
| April 2 |
Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data
Show |
| April 2 |
State of Diabetes in Pittsburgh: Pittsburgh Business Group on
Health Releases Report |
| April 2 |
NIDA Study Identifies Genes That Might Help Some People Abstain
from Smoking |
| April 2 |
Researchers Discover a Common Variation in a Gene Segment that
Increases the Risk for Prostate Cancer |
| April 3 |
Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study
Showing Anti-Cancer Effect with Lead RNAi Candidate |
| April 3 |
Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect
with Lead RNAi Candidate |
| April 3 |
Cell Genesys Provides Final Median Survival Data From Second Phase
2 Trial of GVAX Immunotherapy for Prostate Cancer |
| April 3 |
Opexa Therapeutics Reports Positive Top-line Data in Phase I/II
Dose Escalation Trial with Tovaxin for Multiple Sclerosis |
| April 3 |
Repros' Proellex Shows Statistically Significant Improvement in
Primary Endpoint in Phase 2 Trial in the Treatment of Uterine
Fibroids |
| April 3 |
Latest NIMH Study on Bipolar Disorder |
| April 3 |
Once Daily, Extended-Release Ropinirole Improves Parkinson's
Symptoms in Patients not Optimally Controlled With Levodopa |
| April 3 |
Pharmasset Announces Clevudine and Hepatitis C Presentations at
EASL |
| April 3 |
New Data Show Early Non-Response to Antipsychotic Treatment May Be
Strong Predictor of Subsequent Non-Response for People with
Schizophrenia |
| April 3 |
PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the
Subject of Promising New Alzheimer's Research |
| April 3 |
Targanta Reports Improved Ability of Oritavancin to Stop Bacteria
Growth In Vitro Compared With Other Glycopeptide Antibiotics |
| April 3 |
New Data Confirm That Use of Levemir Can Limit Weight Gain |
| April 3 |
Southern Research Institute to Present at the 2007 American
Association For Cancer Research Annual Meeting |
| April 3 |
Allon Therapeutics to Present New Data at Leerink Swann Alzheimer's
Conference |
| April 3 |
Rapid Response was Crucial to Containing the 1918 Flu Pandemic |
| April 3 |
Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the
Subject of Promising New Alzheimer's Research |
| April 3 |
Scientific Results Presented At ECCMID Demonstrate Well-
Differentiated Profile of Basilea's Two Phase III Anti- infective
Compounds |
| April 4 |
CytoGenix Announces Successful Testing of synDNA Vaccine for Avian
Influenza Virus |
| April 4 |
Novagali Pharma Announces Positive Vekacia Clinical Results From
Pivotal Phase III Trial in Vernal Keratoconjunctivitis |
| April 4 |
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03)
Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival
Advantage for Patients with Multiple Myeloma |
| April 4 |
Survival Data Available from Erbitux Study in First-Line Treatment
of Advanced Head and Neck Cancer |
| April 4 |
Survival Data Available From Erbitux Study in First-Line Treatment
of Advanced Head and Neck Cancer |
| April 4 |
Icagen Terminates Phase III ASSERT Study |
| April 4 |
New Analysis of Data from WHI Provides Reassurance With Respect to
Coronary Heart Disease For Newly Menopausal Women Considering
Hormone Therapy |
| April 4 |
Portola Pharmaceuticals Announces Positive Phase II Results for
PRT054021 for Prevention of Venous Thromboembolism Following Total
Knee Replacement Surgery |
| April 4 |
CytRx Announces Positive Results of Arimoclomol in Preclinical
Stroke Recovery Studies |
| April 4 |
Eurand Announces Positive Phase III Clinical Study Results |
| April 4 |
Nuvelo Announces Presentation on NU206 at 2007 American Association
for Cancer Research Annual Meeting |
| April 4 |
SuperGen to Highlight Oncology Pipeline Data in Multiple
Presentations at AACR |
| April 4 |
Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data
Published in JAMA |
| April 4 |
ARIUS to Present at American Association for Cancer Research Annual
Meeting |
| April 4 |
CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to
be Presented on June 3, 2007 |
| April 4 |
Over 10,000 UK Breast Cancer Patients Could Become Eligible Within
the Next Year for a Breast Cancer Therapy Showing Increased
Survival Rates, Reveals Synovate Healthcare’s European
Oncology Monitor |
| April 5 |
Low-Dose Steroid Combined With Lenalidomide Prolongs Survival
Compared With High-Dose Steroid for Multiple Myeloma Treatment |
| April 5 |
Callisto Intends to Move Guanilib into Clinical Trials in
Ulcerative Colitis |
| April 5 |
Researchers Identify Intracellular Pathway of Alfacell's Onconase |
| April 5 |
The International Myeloma Foundation Says New Clinical Trial
Results Could Improve Survival While Reducing Side Effects For Many
Patients |
| April 5 |
New Cardioprotective Drug Could Provide Boost For Post-Bypass
Surgery Heart Health |
| April 6 |
MIV Therapeutics Announces Pivotal Test Results Further Validating
Company Stent Coatings Meet Critical FDA Fatigue Guidelines |
| April 9 |
Nereus Pharmaceuticals to Present Data at the American Association
for Cancer Research 2007 Annual Meeting |
| April 9 |
Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival
Benefits as Mitigator Against Radiation-Induced Damage in Study |
| April 9 |
The Sturdier Sex?: Study by Pittsburgh Scientists Finds Female Stem
Cells Work Better |
| April 9 |
Cytokinetics Announces Non-clinical Data to be Presented at the
2007 AACR Annual Meeting |
| April 10 |
GSK and Adolor Announce Preliminary Results from Phase 3 Safety
Study of Alvimopan (Entereg/Entrareg) |
| April 10 |
Nasulin Interim Results to Be Presented at American Diabetes
Association Scientific Sessions |
| April 10 |
Kosan Announces Data Presentations at Upcoming AACR Annual Meeting |
| April 10 |
Inotek Pharmaceuticals Announces Publication of Animal Data from
Study of PARP Inhibition as Potential Preventative of Brain Injury
Following Stroke |
| April 10 |
Data Available from Erbitux Phase III Study in First-Line Treatment
of Advanced Pancreatic Cancer |
| April 10 |
Infinity and MedImmune to Present Preclinical Data From Study of
Oral Formulation of IPI-504 At AACR |
| April 10 |
First-of-its-Kind National Report Reveals Estimated High Prevalence
and Heavy Cost of Type 2 Diabetes Complications in America |
| April 10 |
Pharmacopeia Announces Positive Results from Initial DARA Clinical
Trial |
| April 10 |
Avalon Pharmaceuticals to Present at the American Association for
Cancer Research 2007 Annual Meeting |
| April 10 |
Telik Announces Telcyta Clinical and Preclinical Presentations at
AACR Meeting |
| April 10 |
Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases |
| April 10 |
Study Shows Children With ADHD Who Start on Strattera are More
Likely to Change Therapies |
| April 11 |
InterMune Presents Research on ITMN-191 in Hepatitis C at EASL
Annual Meeting |
| April 11 |
Pharmacyclics Announces Presentations on Its Novel and Selective
HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds |
| April 11 |
Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,
Rheumatoid Arthritis and Lymphoma |
| April 11 |
First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone
Was More Cost-Effective Than Interferon Beta Therapies for
Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) |
| April 11 |
Vertex Pharmaceuticals Announces New Data for Investigational HCV
Protease Inhibitor Telaprevir to be Presented at 42nd Annual
Meeting of the European Association for the Study of the Liver
(EASL) |
| April 11 |
New Clinical Study Results Indicate Higher Early Virologic Response
with Celgosivir Combination Therapy in HCV Non-Responders |
| April 11 |
Cyclacel Pharmaceuticals to Present Preclinical Data on
Sapacitabine and Seliciclib at AACR |
| April 11 |
Schering-Plough Addresses Major Milestones and Challenges in
Treatment of Patients With Chronic Hepatitis C |
| April 11 |
Callisto Pharmaceuticals Announces Publication of Research Article
on Atiprimod Preclinical Studies in Mantle Cell Lymphoma |
| April 11 |
Gloucester Pharmaceuticals Announces Multiple Presentations of
Preclinical Romidepsin Data at American Association of Cancer
Research Annual Meeting |
| April 11 |
Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With
Seasonal Influenza Vaccine |
| April 11 |
Nuvelo Announces Publication of NU206 Study Results in
Gastroenterology |
| April 11 |
Newest Adult Stem Therapy Treats Diabetes |
| April 11 |
Fragile X, Down Syndromes Linked to Faulty Brain Communication,
Stanford Researcher Finds |
| April 11 |
Innovive Pharmaceuticals Announces Data from Oncology Drug Programs
to be Presented at American Association for Cancer Research Annual
Meeting |
| April 11 |
Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2
Study Data in Neurology |
| April 12 |
DNA Therapeutics Reports a Novel Mechanism of Action and a
Biomarker of its Lead Molecule Dbait That Open an Innovative
Pathway-Targeting in Molecular Cancer Therapy |
| April 12 |
Idenix Reports Results from Two Phase IIb Studies of the
Combination of Valopicitabine and Pegylated Interferon in Hepatitis
C Genotype-1 Patients at the 42nd Annual Meeting of the European
Association for the Study of the Liver |
| April 12 |
Innovive Pharmaceuticals Announces Additional Data Presentations at
American Association for Cancer Research Annual Meeting |
| April 12 |
Affymax Announces Results From Phase 2 Clinical Trial of Hematide
for the Treatment of Anemia in Dialysis Patients |
| April 12 |
CuraGen Announces New Preclinical Results with Belinostat and
Velafermin to be Presented at AACR Annual Meeting |
| April 12 |
Intarcia Therapeutics Announces Final Results From a Phase 2 Study
of Injectable Omega Interferon plus Ribavirin for the Treatment of
Hepatitis C Genotype-1 |
| April 12 |
Advanced Magnetics Announces Positive Results from Two Additional
Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement
Therapeutic |
| April 12 |
AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical
Pipeline to Be Featured at AACR |
| April 12 |
Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical
Trial Data |
| April 12 |
Hana Biosciences Announces Data to be Presented On Talvesta
(Talotrexin) for Injection at The American Association for Cancer
Research Annual Meeting |
| April 12 |
Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying
to Control It Later |
| April 13 |
ANA380 Exhibits Activity In Vitro Against Multiple Clinically
Relevant Hepatitis B Virus Mutants |
| April 13 |
Enzon to Present Preclinical Data From PEG-SN38 and PEGylation
Technology Studies at AACR Meeting |
| April 13 |
Baraclude (entecavir) Therapy Resulted in Undetectable Levels of
Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment |
| April 13 |
Ascenta Therapeutics Highlights Multiple Data Presentations at
Upcoming AACR Annual Meeting |
| April 13 |
Sunesis Pharmaceuticals to Present Data at the Annual Meeting of
the American Association for Cancer Research |
| April 13 |
Gentium's Defibrotide Highlighted in Two Poster Presentations at
American Association for Cancer Research Annual Meeting |
| April 13 |
Point Therapeutics Announces Preclinical Data Presentations at
Upcoming American Association of Cancer Research Annual Meeting |
| April 13 |
Data Analyses Outline Efficacy and Safety of Mircera for the
Treatment of Renal Anemia Associated With Chronic Kidney Disease |
| April 13 |
Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount
System for Automated Cell Counting at AACR |
| April 13 |
Positive Results Prompt US National Cancer Institute to Make
Gleevec Available To Patients in Post-Surgical Gist Study |
| April 13 |
Positive Results Prompt US National Cancer Institute to Make Glivec
Available to Patients in Post-Surgical GIST Study |
| April 13 |
Abbott Researchers Focus on New Cutting-Edge Approaches in the
Fight Against Cancer |
| April 13 |
ViroPharma Announces Presentation of Additional HCV-796 Data at
Meeting of The European Association for the Study of the Liver |
| April 13 |
AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors
and In Vivo Results for a GHRH Antagonist at the AACR Annual
Meeting in Los Angeles |
| April 13 |
Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001
at American Association of Cancer Research Annual Meeting |
| April 13 |
New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective
Relative to Other Interferon Therapies for Multiple Sclerosis |
| April 13 |
CombinatoRx to Present Combination High Throughput Screening (cHTS)
Data at Upcoming AACR Meeting |
| April 13 |
DX-88 for Hereditary Angioedema Meets Primary and Secondary
Endpoints in Phase 3 Trial (EDEMA3) |
| April 13 |
Cequent Pharmaceuticals Founder to Present tkRNAi Technology at the
American Association of Cancer Research Annual Meeting in Los
Angeles |
| April 13 |
Vion Presents Data on Cloretazine (VNP40101M) at the 100th Annual
Meeting of the American Association of Cancer Research (AACR) |
| April 13 |
UCLA: Lithium Builds Gray Matter in Bipolar Brains, UCLA Study
Shows |
| April 16 |
Rigel to Present New Research Programs at AACR Meeting |
| April 16 |
AEterna Zentaris Discloses First In Vitro Data for its PI3K
Inhibitors at the AACR Annual Meeting in Los Angeles |
| April 16 |
ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR |
| April 16 |
Poster on Cyclosert Drug Delivery Presented at AACR Meeting |
| April 16 |
Access Pharmaceuticals Announces Poster Presentations on ProLindac
at the American Association for Cancer Research 2007 Annual Meeting |
| April 16 |
Novelos Therapeutics and MUSC Present Two Posters at AACR 2007
Annual Meeting |
| April 16 |
Interim Results Presented at EASL from PROVE 1 Clinical Trial of
Investigational Drug Telaprevir in Patients with Genotype 1
Hepatitis C |
| April 16 |
Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine
in Glioma Presented at American Association of Neurological
Surgeons Annual Meeting |
| April 16 |
Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of
CERE-120 Demonstrating Improved Motor Function in Parkinson's
Patients |
| April 16 |
AVAX Technologies Presents Results of Phase I-II M-Vax Trial at
Annual Meeting of American Association for Cancer Research |
| April 16 |
Sunesis Presents Data Supporting SNS-032's Potential Anticancer
Activity in Multiple Myeloma at the American Association for Cancer
Research Meeting |
| April 16 |
Data supporting three Antisoma programmes presented at AACR |
| April 16 |
Genzyme Announces Successful Completion of Study Investigating
Sevelamer Carbonate in Patients With Chronic Kidney Disease |
| April 16 |
Data Presented at AACR Meeting Shows Peregrine's Selective
Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical
Cancer Models |
| April 16 |
Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase
I/IIa 6-Month Results at 75th Annual Meeting of the American
Association of Neurological Surgeons |
| April 16 |
ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR |
| April 16 |
Somanta Announces the Presentation of Alchemix Data at The American
Association for Cancer Research Annual Meeting |
| April 16 |
Expression Genetics, Inc. Announces Successful Completion of Phase
I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer |
| April 16 |
Preclinical Data Show Alfacell's Onconase Inhibits Tumor Growth of
Non-Small Cell Lung Cancer, Breast Cancer Cells |
| April 16 |
Threshold Pharmaceuticals Announces Multiple Presentations on
Oncology Pipeline at the 2007 American Association for Cancer
Research (AACR) Annual Meeting |
| April 16 |
Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic
Drug to Treat Viral Eye Infection |
| April 16 |
Achillion Presents Positive Data on Novel Mechanism for Treating
HCV at EASL Annual Meeting |
| April 16 |
Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving
Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual
Meeting |
| April 16 |
Randomized Phase III Trial Showed Erbitux Significantly Improved
Secondary Endpoints of Progression-Free Survival and Disease
Control in Metastatic Colorectal Cancer Patients |
| April 16 |
Biomira Selects PX-866 as Clinical Development Candidate and
Presents Promising Preclinical Data at AACR |
| April 16 |
Onconova Therapeutics Announces Presentation of Clinical and
Non-Clinical Results for Its Lead Compound ON 01910.Na at American
Association of Cancer Research Conference in Los Angeles |
| April 16 |
Bionovo to Present Recent Findings of BZL101, Its Anti-cancer
Agent, at the American Association of Cancer Research |
| April 16 |
Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference |
| April 16 |
Calando Pharmaceuticals Announces Preclinical Efficacy and Safety
Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting |
| April 16 |
EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in
Preclinical Models |
| April 16 |
Arrowhead Subsidiaries Insert & Calando Present Data on
Cyclosert Drug Delivery System at AACR Meeting |
| April 16 |
Progen's Phase 2 Liver Cancer Trial Exceeds Efficacy Objective |
| April 16 |
Kosan Presents Preclinical Antitumor and Safety Data On
Next-Generation Epothilone KOS-1803 at AACR |
| April 16 |
Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor
Tanespimycin (KOS-953) at AACR |
| April 16 |
Karmanos Physician-Scientists Examine Racial Disparities in
Patients with Gynecologic Cancer |
| April 16 |
Research Supported by Samuel Waxman Cancer Research Foundation
Discovers Mode of Action of Arsenic-Based Drugs in Destroying
Cancer Cells |
| April 17 |
AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist
JMR-132 at the AACR Annual Meeting in Los Angeles |
| April 17 |
Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces
a Broad, Patient-Specific Antibody Response |
| April 17 |
EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR
Annual Meeting |
| April 17 |
GTx Announces Ostarine Improved Insulin Resistance among Elderly
Patients in a Recently Completed Phase II Clinical Trial |
| April 17 |
Telik Reports Positive Data Demonstrating Synergy in Combination
and Highly Statistically Significant Effect of Telcyta as
Maintenance Therapy in First-Line Non-Small Cell Lung Cancer |
| April 17 |
Addex Achieves Statistically Significant Outcome in Phase IIa
Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease |
| April 17 |
GenVec Announces New Research at AACR on Selectivity and Mechanism
of Action of TNF-Based Anti-Cancer Therapy |
| April 17 |
ProNAi Announces Preclinical Success for PNT2258 Therapeutic -
Curative Events in Xenograft Mice for Difficult-to-Treat
Non-Hodgkin's Lymphoma |
| April 17 |
Curis Announces Hedgehog and Wnt Antagonist Data Presentation at
AACR |
| April 17 |
ArteFill 5-Year Data to Be Presented at American Society for
Aesthetic Plastic Surgery Annual Meeting |
| April 17 |
Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor
Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in
Cancer Animal Models |
| April 17 |
Data Published in Neurology Showed That Higher Dose of Copaxone
Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) |
| April 17 |
Millennium Discovers Biomarkers Potentially Predictive of Response
to Velcade (Bortezomib) for Injection |
| April 17 |
AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral
Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and
Drug-Resistant Lung Cancer |
| April 17 |
Oncolytics Biotech Inc. Research Collaborators Demonstrate
Reovirus/Gemcitabine Combination Has Synergistic Effect Against
Human Colon Cancer Cell Lines |
| April 17 |
Lorus Therapeutics Announces Scientific Presentations for Lead
Antisense and siRNA Drug Candidates at International Cancer
Conference |
| April 17 |
OncoGenex Technologies Announces Phase II Data of OGX-011 in
Metastatic Breast Cancer at American Association for Cancer
Research 2007 Annual Meeting |
| April 17 |
Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor
Activity of Natural Killer Cells |
| April 17 |
Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus
Docetaxel Reduces Growth of Both Hormone-Dependent and
Hormone-Independent Prostate Cancer by Up to 94 Percent in
Preclinical Studies |
| April 17 |
Alzheimer's Drug Shows Promise in Fighting Cancer |
| April 17 |
Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR
Annual Meeting Late-Breaking Clinical Trials Session |
| April 17 |
Alnylam Announces Advancement of a New RNAi Therapeutic Development
Program for the Treatment of Liver Cancer |
| April 17 |
Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100
Percent Protection Against Precancerous Lesions Caused By
Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than
Five Years |
| April 17 |
ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR |
| April 17 |
Æterna Zentaris Discloses First In Vitro Data for its PI3K
Inhibitors at the AACR Annual Meeting in Los Angeles |
| April 17 |
Data on Higher Dose of Copaxone and Data Showing Copaxone is Most
Cost Effective |
| April 17 |
Adnexus Therapeutics Announces Presentation at the American
Association for Cancer Research (AACR) on Clinical Product
Candidate, CT-322 |
| April 17 |
Myriad Genetics Presents Azixa's Mode of Action at AACR |
| April 18 |
Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC
Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with
Bruton's Tyrosine Kinase Inhibitors |
| April 18 |
Avanir Pharmaceuticals Announces Positive Results of Phase III
Study for Zenvia in Diabetic Neuropathic Pain |
| April 18 |
Gemin X Presents Positive Preclinical Data of GX15-070 in Infant
ALL at AACR Meeting |
| April 18 |
Onconase has Potential as Chemopreventive Agent in Mesothelioma,
Reports World-Renowned Mesothelioma Researcher at AACR Annual
Meeting |
| April 18 |
Idera Pharmaceuticals Announces Presentations of Preclinical Data
on New Potential Oncology Applications of its TLR9 Agonists at AACR |
| April 18 |
Data Presented at AACR Meeting Show Peregrine's Bavituximab
Equivalent Can Generate Curative Immune Responses as Part of a
Vaccine-Like Regimen in Preclinical Models of Aggressive Brain
Cancer |
| April 18 |
EPIX Pharmaceuticals Announces Statistically Significant Results in
Cognitive Function from Phase 1b Clinical Trial of Novel 5-HT6 Drug
Candidate |
| April 18 |
Aeolus Pharmaceuticals' AEOL 10150 Highlighted in Nature Genetics
Publication |
| April 18 |
Ferring Reports on ENDOMETRIN Presentations at Pacific Coast
Reproductive Society Annual Meeting |
| April 18 |
Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207
for BPH |
| April 18 |
Helix BioMedix to Discuss Potential of Its Proprietary Peptides at
the BIO International Convention |
| April 18 |
Innovive Pharmaceuticals Announces Preclinical Data from INNO-206
Oncology Program |
| April 18 |
Viventia biotech reports synergystic effect of its Proxinium
antibody in combinaton with chemotherapy and radiation |
| April 18 |
Adventrx Announces Positive Data From Multidrug Therapy With
CoFactor |
| April 18 |
Seattle Genetics Highlights Data on its Proprietary Antibody-Drug
Conjugate Technology at AACR |
| April 18 |
Santaris Pharma presents positive preclinical data on SPC2996 at
the American Association for Cancer Research |
| April 18 |
Micromet and MedImmune Present Data From Preclinical Study of New
BiTE Molecule Targeting CEA |
| April 18 |
Protalix BioTherapeutics, Inc. Receives Approval from the FDA to
Initiate a Phase III Clinical Trial of prGCD |
| April 18 |
Favrille Announces Results From Study Showing Enhanced Activity
From Insect Cell-Derived Immunotherapy for Lymphoma |
| April 18 |
Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel
Anticancer Agents, at AACR |
| April 18 |
Data Presented at AACR Meeting Shows Peregrine's Immunocytokine
Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in
Preclinical Studies |
| April 18 |
Micell Technologies Presents Data on Novel Drug-Eluting Stents |
| April 18 |
FDA Announces Change of Location Notice for Upcoming Advisory
Committee Meeting |
| April 18 |
Gloucester Pharmaceuticals Reports on Romidepsin and Erlotinib
Combination in Non-Small Cell Lung Cancer Presented at American
Association of Cancer Research Annual Meeting |
| April 18 |
Myriad Genetics Presents Tumor Origin Technology at AACR |
| April 18 |
Novel Human Tissue Transgenic Cancer Model May Offer Significant
Advance Toward Accurately Modeling Human Cancer |
| April 19 |
Antares Pharma Announces Positive Results from Application Site
Study for Anturol |
| April 19 |
ImClone Systems Showcases Extensive Research and Development
Program at the AACR Annual Meeting |
| April 19 |
Allos Therapeutics' PDX Granted Orphan Medicinal Product
Designation by the European Commission |
| April 19 |
MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE
Molecule |
| April 19 |
CuraGen and TopoTarget Announce New Clinical Results With
Belinostat to be Reported at Upcoming Major Medical Meetings |
| April 19 |
EntreMed Presents Preclinical Data for MKC-1 in Hematological
Cancers |
| April 19 |
Abraxis BioScience Presents Pre-Clinical Findings That Support Role
of SPARC Expression in Cancer and the Role of the Nanoparticle
Albumin Bound (nab) Technology Platform in Targeting the Pathway |
| April 19 |
Abraxis BioScience Presents Results from Pre-Clinical Study That
Demonstrates nab-Rapamycin's Robust Antitumor Properties and
Ability to Target Intracellular Sites Such as the mTOR Pathway |
| April 19 |
Othera Pharmaceuticals Announces Upcoming Presentation Based Upon
Expanded Understanding of Lead Compound Mechanism of Action |
| April 19 |
Abraxis BioScience Presents Data from Pre-Clinical Study That
Provide Evidence for Chemotherapy-Induced Angiogenesis and
Rationale for Combining nab-Paclitaxel (Abraxane) with
Anti-Angiogenic Agents to Increase Tumor Response |
| April 19 |
Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor
Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 |
| April 19 |
Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment
of HCV |
| April 19 |
King Pharmaceuticals Announces Plan to Report Positive Data from
Phase III Clinical Trial Evaluating the Combination of Altace with
Hydrochlorothiazide |
| April 19 |
Aranesp ``145 Study'' Shows No Difference in Survival in Patients
with Small-Cell Lung Cancer |
| April 19 |
Spectrum Pharmaceuticals Announces Data From Three Oncology
Programs Presented at the American Association of Cancer Research
Annual Meeting |
| April 19 |
Aeolus Pharmaceuticals' AEOL 10113 Demonstrates Potential as a
Protector of Healthy Normal Cells from Cancer Radiation Therapy |
| April 19 |
Lexicon-Genentech Collaboration Yields Potential Therapeutic
Targets |
| April 19 |
Critical Therapeutics Announces the Publication of New Preclincial
HMGB1 Data in Nature Immunology |
| April 19 |
Idenix Announces Data Presentations at the 2007 Digestive Disease
Week Meeting |
| April 19 |
MedImmune Publishes New Data in Nature Immunology Demonstrating The
Role HMGB1 May Play in Systemic Autoimmune Diseases |
| April 19 |
LANI completes Phase I in Japan and to commence Phase I in UK |
| April 19 |
VioQuest Pharmaceuticals Announces Data Presentation for Its Akt
Inhibitor VQD-002, at American Association for Cancer Research
Annual Meeting |
| April 20 |
Addex Reports Positive Results in Phase IIa Clinical Trial With
ADX10059 in Migraine |
| April 20 |
Gilead Announces Presentation of Positive Phase III Data on
Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis |
| April 20 |
New Anti-Rejection Medication 6-Month Results for Heart Transplant
Recipients to Be Released at International Heart and Lung
Transplant Meeting |
| April 20 |
Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR |
| April 20 |
The Lancet Publishes PREVAIL Study Results Showing Lovenox
Superiority Over Unfractionated Heparin for Reducing the Risk of
Venous ThromboEmbolism in Patients With Acute Ischemic Stroke |
| April 20 |
UCB Announces Positive Top-Line Phase III Results for Keppra as
Adjunctive Therapy for Partial Onset Seizures in Paediatric
Patients from One Month to Less than Four Years of Age |
| April 20 |
Baxter Presents Phase I Inhaled Insulin Study Results at
Respiratory Drug Delivery Conference |
| April 20 |
Peregrine Pharmaceuticals Highlights Significant Advances in the
Company's Clinical and Preclinical Cancer Programs Presented This
Week at the AACR Annual Meeting |
| April 20 |
FDA Announces Audio Broadcasts on Emerging Drug Safety Information |
| April 23 |
Micromet Achieves Milestone in BiTE Research Collaboration with
MedImmune |
| April 23 |
Positive Results Using Affitech-Identified Human Antibody That
Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model
Reported by Peregrine |
| April 23 |
Ceragenix Announces New Publication of Scientific Research on
Ceragenin Technology |
| April 23 |
Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month
Hematide for the Treatment of Anemia in Patients with Early- and
End-Stage Chronic Kidney Disease |
| April 23 |
CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively
Licensed to Subsidiary, RXi Pharmaceuticals, Described in
Peer-Reviewed Journal |
| April 23 |
Sirion Therapeutics Announces Clinical Data to be Presented at the
2007 Association for Research in Vision and Ophthalmology (ARVO)
Annual Meeting |
| April 23 |
FDA MedWatch: Avastin (bevacizumab) and Formation of
Tracheoesophageal Fistula in a Recent Clinical Study in Patients
with Limited-stage Small Cell Lung Cancer |
| April 23 |
Cellerant Therapeutics Reversed Autoimmune Disease in Lupus Mice
with Transplant of Purified Donor Blood Stem Cells |
| April 23 |
Aeolus Pharmaceuticals' AEOL 10113 May Play an Important Role
Regulating the Oxidative Damage Induced by Ionizing Radiation |
| April 23 |
Mircera Effective in Stabilising Haemoglobin Levels in Elderly
Patients With Kidney Disease on Dialysis |
| April 23 |
Targeting Specific Mutations Reveals Promising New Approach to
Treating Genetic Disorders; Preclinical Data Published in Nature |
| April 23 |
Gentium's Defibrotide Highlighted in Poster Presentation at World
Congress of Nephrology |
| April 24 |
New Data Show Xenical Significantly Reduces Cardiovascular Risk and
More Than Doubles Weight Loss Achieved in Overweight and Obese
People |
| April 24 |
Medivation Announces First U.S. Presentation of Data From Dimebon
Phase 2 Alzheimer's Disease Trial at American Academy of Neurology
Annual Meeting |
| April 24 |
Amarin Reports Top-Line Results of two Phase III Studies of
Miraxion in Huntington's Disease |
| April 24 |
Ceragenix Announces Results from Phase IV Study of EpiCeram Meet
All Primary and Secondary Endpoints |
| April 24 |
Accera, Inc. to Present Results of Phase II Study in Alzheimer's
Disease at American Academy of Neurology Meeting |
| April 24 |
Prospective Model Outlined Potential Time and Cost Savings of
Once-Monthly Anemia Treatment |
| April 24 |
FDA approves MyocondaR IND for MAP in Crohn's Disease |
| April 24 |
Cortex Area Thinner in Youth with Alzheimers-Related Gene |
| April 25 |
Telomerase Presentations at the AACR 2007 Annual Meeting |
| April 25 |
Acorda Therapeutics to Host Analyst and Investor Reception |
| April 25 |
BDSI Announces Positive Phase III Clinical Trial Results for BEMA
Fentanyl |
| April 25 |
ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic
Testing of ANX-514 (Docetaxel Emulsion) |
| April 25 |
Basilea Reports Positive Re-treatment Results from a Second Phase
III Trial of Alitretinoin for Patients with Severe Chronic Hand
Eczema |
| April 25 |
XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512
in Restless Legs Syndrome |
| April 25 |
DuoCort AB: DuoCort announces Phase I Data Presentation at the
European Congress of Endocrinology |
| April 25 |
Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer |
| April 25 |
OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study
Published in the Journal of Clinical Oncology Showed Survival
Improvement in Patients with Pancreatic Cancer |
| April 25 |
New Data on Genmab and GlaxoSmithKline's Ofatumumab: Phase II Study
in Rheumatoid Arthritis to be Presented at EULAR |
| April 25 |
Bipolar Disorder in Children Difficult to Diagnose, Reports the
Harvard Mental Health Letter |
| April 25 |
Preclinical Studies Identify Novel Approach for Enhancing the
Anticancer Activity of Introgen's INGN 241 |
| April 25 |
Labtec’s Next Generation Pain Patch Successful in Clinical
Studies |
| April 26 |
Columbia Laboratories Reports Preliminary Findings from the Ongoing
Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%
(progesterone gel) to Prevent Preterm Birth |
| April 26 |
Major Manufacturer of Unapproved and Adulterated Drugs |
| April 26 |
Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for
Travelers' Diarrhea Stimulates Immune Response Even at Low Doses |
| April 26 |
Study Demonstrating Aeolus Compound's Neuroprotection in
Parkinson's Disease Published in the Journal of Neuroscience |
| April 26 |
Study Supports Cost-Effectiveness of Medtronic's Spasticity
Treatment for Children with Cerebral Palsy |
| April 26 |
Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP
Phase II Trial |
| April 26 |
Ties Between Physicians and Drug Companies Still Too Strong: the
Prescription Project Offers Solutions to Prevent Conflicts of
Interest |
| April 26 |
Schepens Scientists Identify Key to Integrating Transplanted Nerve
Cells Into Injured Tissue |
| April 26 |
FDA approves IND on Lead Product M6G |
| April 26 |
Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh
to be Presented at European Vascular Symposium |
| April 26 |
Researchers Identify New Genetic Risk Factors for Type 2 Diabetes |
| April 27 |
First Controlled Large-Scale Intervention Angiotensin Receptor
Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study
Demonstrates Significant Reduction in Blood Pressure and Protection
of Organs with Valsartan |
| April 27 |
Doctors Outraged Over Growth Hormone Controversy |
| April 27 |
Northfield Laboratories Investor Update |
| April 27 |
Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events
in Landmark Jikei Heart Study |
| April 27 |
Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events
in Landmark Jikei Heart Study |
| April 27 |
Human Genome Sciences Reports Growing Evidence That Its TRAIL
Receptor Antibodies Have Significant Potential in the Treatment of
a Broad Range of Cancers |
| April 27 |
SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO |
| April 27 |
Merck Serono Announces Presentation of Phase III Clinical Data on
Safinamide in Parkinson’s Disease at the American Academy of
Neurology 59th Annual Meeting |
| April 30 |
Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory
Dose Doxycycline for the Treatment of Rosacea |
| April 30 |
Cobalis Expects to Report Phase III Top-Line Results in May |
| April 30 |
Newly Published Study Reveals Femara Improves Chances for Harder to
Treat Early Breast Cancer Relapse in Postmenopausal Women |
| April 30 |
New Report Illuminates Ampligen's Unique Mechanism of Action |
| April 30 |
Insmed Releases Positive Results from Iplex Phase II HIV-Associated
Adipose Redistribution Syndrome Clinical Study |
| April 30 |
Evidence of Nanoparticles Found in Plaque-Filled Arteries |
| April 30 |
Eighty-one Percent of U.S. Adults say that Birth Control Pills and
Procedures Should Be Covered by Health Insurance |
| April 30 |
Apollo develops needle-free topical vaccine |
| April 30 |
Ad hoc: Interim report about clinical trial of BF-200 ALA in
actinic keratosis |
